Entinostat (MS-275)

For research use only.

Catalog No.S1053 Synonyms: SNDX-275

308 publications

Entinostat (MS-275) Chemical Structure

CAS No. 209783-80-2

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 89 In stock
EUR 95 In stock
EUR 147 In stock
EUR 265 In stock
EUR 756 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Entinostat (MS-275) has been cited by 308 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 NVXLUJJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrKWZZCUUN3ME2wMlA3OSEQvF2= MXrTRW5ITVJ?
ALL-PO MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\6flVKSzVyPUCuNFY{PTVizszN M3HG[nNCVkeHUh?=
697 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPDW4I3UUN3ME2wMlA6QTd4IN88US=> M1jLeXNCVkeHUh?=
NCI-H748 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HydGlEPTB;MD6xNFM{PCEQvF2= MlXCV2FPT0WU
NKM-1 Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWiwc2xpUUN3ME2wMlExQTF{IN88US=> NXjrR2hQW0GQR1XS
ES1 M{iwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDPTWM2OD1yLkGxNlU2KM7:TR?= MVLTRW5ITVJ?
NCI-H1963 NHLNXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP3b|ZKSzVyPUCuNVE2PzlizszN NHjXOppUSU6JRWK=
NCI-H1417 NGTYS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoGzTWM2OD1yLkGyPVc1KM7:TR?= M{jRS3NCVkeHUh?=
NEC8 M4jGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zNW2lEPTB;MD6xN|UzPyEQvF2= MVPTRW5ITVJ?
CRO-AP2 NH\DOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwMU[4PFkh|ryP NEDx[ZNUSU6JRWK=
A3-KAW NF20TZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq4bmVKSzVyPUCuNVc3OjdizszN NHT0VJZUSU6JRWK=
SF539 M2TqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwMUm1PVMh|ryP MX7TRW5ITVJ?
NOS-1 M364Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33VfWlEPTB;MD6xPVYyQSEQvF2= M4XZSXNCVkeHUh?=
NTERA-S-cl-D1 MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMkCxNVMh|ryP M1XwPXNCVkeHUh?=
COR-L88 MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHicGN7UUN3ME2wMlIzQTV7IN88US=> MUDTRW5ITVJ?
EM-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMkSwO|kh|ryP MofDV2FPT0WU
KARPAS-45 Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDMRYZKSzVyPUCuNlc5OzNizszN MmjNV2FPT0WU
DSH1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:yT2lEPTB;MD6yPFcxQCEQvF2= MlvoV2FPT0WU
HT-144 NHS3Z5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TlVmlEPTB;MD6zNFI2PiEQvF2= MVfTRW5ITVJ?
ATN-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHe3W45KSzVyPUCuN|A2PzZizszN NWfJR4Z3W0GQR1XS
HEL MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n0Z2lEPTB;MD6zNVM1QCEQvF2= M4LBOXNCVkeHUh?=
NB12 M3vTfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDKeY5DUUN3ME2wMlMyPzV4IN88US=> MmnyV2FPT0WU
LU-139 M{G2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2mySGlEPTB;MD6zN|UyKM7:TR?= Ml7UV2FPT0WU
J-RT3-T3-5 M{Twfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:1VpFTUUN3ME2wMlM{PzF4IN88US=> MY\TRW5ITVJ?
MOLT-13 M{PXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwM{O4NUDPxE1? MWTTRW5ITVJ?
SR MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q4UWlEPTB;MD6zOFI3OSEQvF2= NH;FemNUSU6JRWK=
CMK MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1j5d2lEPTB;MD6zOVczPyEQvF2= M2TafXNCVkeHUh?=
ES8 NIH1b|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwM{[wNlIh|ryP MWXTRW5ITVJ?
LB647-SCLC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HjfWlEPTB;MD6zOlc{KM7:TR?= NFz0SWtUSU6JRWK=
TE-8 MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwM{[5N|Uh|ryP NIm5V25USU6JRWK=
BV-173 MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYe2VI5vUUN3ME2wMlM4OTJzIN88US=> NEDPe3NUSU6JRWK=
DEL MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkf5TWM2OD1yLkO3OFg4KM7:TR?= Mm\aV2FPT0WU
ARH-77 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLvTWM2OD1yLkO4NVk{KM7:TR?= NX;aWG9zW0GQR1XS
NCCIT MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrJeWdKSzVyPUCuN|g3PDlizszN NFnR[5FUSU6JRWK=
RPMI-8402 M1m1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fvcGlEPTB;MD6zPFcxOSEQvF2= NXvVdWJrW0GQR1XS
MONO-MAC-6 M{DzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX6UlJZUUN3ME2wMlM5Pzd4IN88US=> M1fVTXNCVkeHUh?=
SK-MM-2 NHTBTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{W2T2lEPTB;MD6zPVg3QCEQvF2= NUXifow6W0GQR1XS
CHP-126 NUD2[WZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M124XmlEPTB;MD60NFI{OSEQvF2= NIG1NoVUSU6JRWK=
A101D MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwNECzJO69VQ>? MVjTRW5ITVJ?
SCH NEHEVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTGTWM2OD1yLkSwN|QzKM7:TR?= M3yzN3NCVkeHUh?=
NMC-G1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\wSGE{UUN3ME2wMlQxOzZ5IN88US=> MXPTRW5ITVJ?
NCI-H209 MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\MTWM2OD1yLkSwOlE{KM7:TR?= NEf0bmlUSU6JRWK=
MOLT-16 M1y4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2iwU2lEPTB;MD60NVAyPyEQvF2= M1TueHNCVkeHUh?=
RPMI-6666 NHLaVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\IRnhKSzVyPUCuOFEyOiEQvF2= MnLtV2FPT0WU
OPM-2 NHzFS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\2b5oyUUN3ME2wMlQyPTF|IN88US=> MYXTRW5ITVJ?
MRK-nu-1 M2DiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHjdHBEUUN3ME2wMlQ{OTV|IN88US=> MV\TRW5ITVJ?
BC-1 M2nTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjY[IJLUUN3ME2wMlQ{PDB|IN88US=> MVvTRW5ITVJ?
MHH-NB-11 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[xTWM2OD1yLkSzOFU{KM7:TR?= NEjS[2JUSU6JRWK=
Ramos-2G6-4C10 MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLZTWM2OD1yLkSzPFk4KM7:TR?= MojpV2FPT0WU
LS-513 MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK4TWM2OD1yLkS0OVAyKM7:TR?= MXTTRW5ITVJ?
K5 NV\LT5FJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3LclZoUUN3ME2wMlQ4ODJ3IN88US=> NGK4Wo9USU6JRWK=
HOP-62 NUjHPHJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUi5c|VjUUN3ME2wMlQ5OzV6IN88US=> NWjKVZpuW0GQR1XS
NCI-H187 NUXFcY5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHjZ|ZqUUN3ME2wMlQ6OjJ5IN88US=> NYGxd4RlW0GQR1XS
BE-13 NHLvfoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\GN4hKSzVyPUCuOFk3PjFizszN M1zsdHNCVkeHUh?=
HC-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[5W2lEPTB;MD61NFQ4OyEQvF2= M{KwSHNCVkeHUh?=
ACN MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDiTWM2OD1yLkWxNFI5KM7:TR?= NFHM[nhUSU6JRWK=
HCC1599 M4XkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrsRYxFUUN3ME2wMlUyPTdizszN MUTTRW5ITVJ?
MV-4-11 M3rFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13n[2lEPTB;MD61N|A1OSEQvF2= M4H2eHNCVkeHUh?=
LC-2-ad Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF30U2RKSzVyPUCuOVM3PjNizszN NUGzOnh5W0GQR1XS
HL-60 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PFNWlEPTB;MD61OFI3OSEQvF2= NEPTOFVUSU6JRWK=
NB17 M{izVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojFTWM2OD1yLkW0N|gh|ryP NF\VNGZUSU6JRWK=
TE-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwNUWzNFYh|ryP M4LJXHNCVkeHUh?=
NCI-H524 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwNUW0NFEh|ryP MlznV2FPT0WU
MZ7-mel Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTiTnNNUUN3ME2wMlU3OTB3IN88US=> M4fhb3NCVkeHUh?=
L-363 NHmzfmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwNU[2OVch|ryP MX7TRW5ITVJ?
BL-41 MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwNU[4PFkh|ryP MknzV2FPT0WU
LU-134-A NV\hc|EzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPITWM2OD1yLkW3NFc{KM7:TR?= M4D0fHNCVkeHUh?=
SIG-M5 MnvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3Je5JKSzVyPUCuOVc5PDhizszN NWfFUFZUW0GQR1XS
ONS-76 M{DEV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPyV|hKSzVyPUCuOVgzPDJizszN NFTBTGhUSU6JRWK=
KARPAS-299 Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofDTWM2OD1yLkW4OVA1KM7:TR?= M33sfHNCVkeHUh?=
DU-4475 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLrTWM2OD1yLkW4O|A{KM7:TR?= NX3ofWZwW0GQR1XS
NB69 NV;hblhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfjTWM2OD1yLkW5PFI2KM7:TR?= NFTXT5NUSU6JRWK=
MHH-PREB-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwNkC3NVkh|ryP NUnOS|VYW0GQR1XS
LU-165 NFrqWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ez[WlEPTB;MD62NVgyOiEQvF2= MlLjV2FPT0WU
LOUCY M1u4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jCUmlEPTB;MD62N|M3PCEQvF2= NYHQc2t4W0GQR1XS
NCI-H526 MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHvXnVMUUN3ME2wMlY{PTRzIN88US=> MkDwV2FPT0WU
KE-37 NEnOVodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vSUmlEPTB;MD62OFI4PiEQvF2= NEe4Z45USU6JRWK=
NALM-6 Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XOXWlEPTB;MD62OFg3KM7:TR?= M3;xb3NCVkeHUh?=
CW-2 NYHMb2hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Dt[WlEPTB;MD62OVc6PCEQvF2= M3jpR3NCVkeHUh?=
SU-DHL-1 M4XzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XIc2lEPTB;MD62OVk1PyEQvF2= NWi5SJF{W0GQR1XS
NB13 NXrjd441T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwNk[4NVch|ryP MnrsV2FPT0WU
QIMR-WIL NUHpeplXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorJTWM2OD1yLk[4N|Q{KM7:TR?= NYe4e|dNW0GQR1XS
ECC12 Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{K5OGlEPTB;MD63NFA5PiEQvF2= NIrGe4tUSU6JRWK=
KALS-1 M3m2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vEN2lEPTB;MD63NFQ6OiEQvF2= MUXTRW5ITVJ?
COR-L279 M2nmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TKbGlEPTB;MD63NFk6PiEQvF2= MnPHV2FPT0WU
NB14 NEDveVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTCTWM2OD1yLkeyOlE4KM7:TR?= NXny[nZYW0GQR1XS
CCRF-CEM NFrNZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT5TWM2OD1yLke0OlYyKM7:TR?= M3ftW3NCVkeHUh?=
SW954 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwN{W5PVkh|ryP NGTYVnVUSU6JRWK=
IST-SL1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofSTWM2OD1yLke3N|Q5KM7:TR?= NGnpb4FUSU6JRWK=
LAMA-84 M{X0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUP4SpdvUUN3ME2wMlc4PTZ5IN88US=> NH[0PJJUSU6JRWK=
Daudi NXHUZo17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwN{e2PFEh|ryP NIO5bFlUSU6JRWK=
BC-3 Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nKeWlEPTB;MD63PFMxQCEQvF2= M{ewVHNCVkeHUh?=
HCC2998 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LGdWlEPTB;MD63PFM3KM7:TR?= MmDXV2FPT0WU
NCI-H69 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TWW2lEPTB;MD64NFE1PyEQvF2= M2DuSXNCVkeHUh?=
CPC-N Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC1c4lKSzVyPUCuPFA2OjRizszN NW\2cpVTW0GQR1XS
NOMO-1 NVf2R4ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwOEGwPFQh|ryP M3Xud3NCVkeHUh?=
CESS MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHWTWM2OD1yLkixNVk4KM7:TR?= MXrTRW5ITVJ?
LC4-1 M4i1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwOESwNFch|ryP NFvlfXRUSU6JRWK=
BL-70 NWP6b2h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwOEW3NFIh|ryP NYTWOVFOW0GQR1XS
ES4 NHHhVI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XldWlEPTB;MD64OVg3QCEQvF2= NIr1bZVUSU6JRWK=
HCE-T NFnxXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLHSmpKSzVyPUCuPFcyPzFizszN MmLmV2FPT0WU
JAR M1fzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX61eW5tUUN3ME2wMlg4QDJ5IN88US=> MlLPV2FPT0WU
ST486 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwOEe5NVch|ryP MoHrV2FPT0WU
KS-1 NVO1eZJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXGTWM2OD1yLki4NFk3KM7:TR?= MkH2V2FPT0WU
GDM-1 NF\VSnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDncmtKSzVyPUCuPFg3QDdizszN M12wO3NCVkeHUh?=
EHEB NV\yU|k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPHZllKSzVyPUCuPVI2QDVizszN MUTTRW5ITVJ?
LB2518-MEL MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwOUOyPFQh|ryP M3PUfnNCVkeHUh?=
GOTO NUL3b|ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwOUWwO|Yh|ryP NX\oXIxOW0GQR1XS
LXF-289 NXXWUIpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonDTWM2OD1yLkm1PVAyKM7:TR?= M4HT[nNCVkeHUh?=
ES6 NHjiTphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnrZ|Z5UUN3ME2wMlk3PDN5IN88US=> NFL3NVJUSU6JRWK=
OS-RC-2 M1fSeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwOU[4N{DPxE1? Mkn6V2FPT0WU
DMS-153 NUjv[XBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr2TWM2OD1yLkm3OFY6KM7:TR?= NHL4UJVUSU6JRWK=
SK-PN-DW M1XjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfrZ5FKSzVyPUCuPVc5OzFizszN NXrXOpZQW0GQR1XS
HH NIDKVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHJUW1iUUN3ME2wMlk5QTV7IN88US=> MYTTRW5ITVJ?
SH-4 Mm\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX1WnBoUUN3ME2xMlAzPDFizszN M{K2OnNCVkeHUh?=
MOLT-4 MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPwfo1KSzVyPUGuNFM1PTRizszN M4DYZnNCVkeHUh?=
TGW NV6wN44zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDpNnJKSzVyPUGuNFc3PzVizszN MVTTRW5ITVJ?
L-540 NWfndm52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnPWYNKSzVyPUGuNVA3ODRizszN NWjR[4ZqW0GQR1XS
PF-382 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTFwMUG1NVMh|ryP MYXTRW5ITVJ?
LC-1F NIj3XY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LLU2lEPTB;MT6xNlAxPyEQvF2= M{TpT3NCVkeHUh?=
OVCAR-4 NGrIbFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojKTWM2OD1zLkGzNVY2KM7:TR?= NFP3O2xUSU6JRWK=
A4-Fuk NEnGVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[2N4VKSzVyPUGuNVU{PjRizszN MoLLV2FPT0WU
HCC2218 NVfDfFh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwMU[2OFEh|ryP MkD2V2FPT0WU
HAL-01 MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFwMU[5OFMh|ryP NEDZS5dUSU6JRWK=
IST-MEL1 M4GzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PVNGlEPTB;MT6xO|Y2QSEQvF2= MWTTRW5ITVJ?
NCI-H719 NUK1XlZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\vTWM2OD1zLkG3PFk5KM7:TR?= NF;nb4pUSU6JRWK=
EVSA-T NF35TY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LSdmlEPTB;MT6xPFEyPCEQvF2= NUT0eY1HW0GQR1XS
SK-NEP-1 NWfHeVdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFwMkCyOlYh|ryP MoXiV2FPT0WU
OCUB-M NFzPepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofnTWM2OD1zLkKxOFg6KM7:TR?= MV7TRW5ITVJ?
MEG-01 M33OXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInKfXJKSzVyPUGuNlIyOThizszN MUPTRW5ITVJ?
no-10 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIC2fFZKSzVyPUGuNlMyOTJizszN NHXXbopUSU6JRWK=
MHH-CALL-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3yTWM2OD1zLkK0O|IyKM7:TR?= NEnROVRUSU6JRWK=
SK-N-DZ MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj4S3BRUUN3ME2xMlI1Pzd4IN88US=> NUKze5ZXW0GQR1XS
SCLC-21H MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTFwMk[0O|gh|ryP M2qwTHNCVkeHUh?=
CTV-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrlcHpOUUN3ME2xMlI4PDJ3IN88US=> MVHTRW5ITVJ?
NB1 NUm2dJRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFwMke3N|Ih|ryP MWXTRW5ITVJ?
NCI-H64 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnveXdKSzVyPUGuNlg1PjJizszN MoC1V2FPT0WU
MDA-MB-134-VI NHL1S|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLoTWM2OD1zLkK4OVc4KM7:TR?= MX7TRW5ITVJ?
LB2241-RCC NFfVTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDGWmRKSzVyPUGuNlg3PjNizszN M1ToRXNCVkeHUh?=
8-MG-BA M3nlUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XqU2lEPTB;MT6yPFg3PiEQvF2= Mk\ZV2FPT0WU
LP-1 NGTXZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTFwMkm5OFch|ryP NFvrSHpUSU6JRWK=
LS-411N MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTFwM{C5PVgh|ryP NUKyc45jW0GQR1XS
CAL-148 M3jNUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTFwM{K1OFIh|ryP MULTRW5ITVJ?
NCI-H2171 M3LkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXvU5VKSzVyPUGuN|Q2ODJizszN Ml\qV2FPT0WU
JiyoyeP-2003 NETXWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrC[IplUUN3ME2xMlM2OzlizszN MXPTRW5ITVJ?
NCI-H2107 M{naOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH5[mdKSzVyPUGuN|U5QDNizszN NEXjRYFUSU6JRWK=
BB30-HNC MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTFwM{i5O|gh|ryP NG\6W|FUSU6JRWK=
K-562 M{iyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVSzR3hFUUN3ME2xMlM6OjF7IN88US=> MmXSV2FPT0WU
PSN1 NGfJ[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFwNEKyPFch|ryP MXrTRW5ITVJ?
HCC2157 Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mln3TWM2OD1zLkSyOlkyKM7:TR?= NFnNfnlUSU6JRWK=
SBC-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\6NmlEPTB;MT60Nlc1OSEQvF2= NHr3RoxUSU6JRWK=
MC116 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFwNEO2NVUh|ryP MVjTRW5ITVJ?
KARPAS-422 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3GzR2lEPTB;MT60OVM2QCEQvF2= Ml62V2FPT0WU
LB996-RCC NFu2NnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHaWJNKSzVyPUGuOFcyODNizszN M3rue3NCVkeHUh?=
MSTO-211H NXjrNGI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfsS5huUUN3ME2xMlQ4QTh5IN88US=> NFL4NZNUSU6JRWK=
BT-474 MoL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTr[GNKSzVyPUGuOVE4PjRizszN NVn2SIF3W0GQR1XS
A388 M3fL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj3W4czUUN3ME2xMlUyQTR3IN88US=> M{DJXXNCVkeHUh?=
SJSA-1 M4fhPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDifoFKSzVyPUGuOVIzPiEQvF2= MoLvV2FPT0WU
COLO-829 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWqzblJQUUN3ME2xMlU{PTZ2IN88US=> MWTTRW5ITVJ?
KM-H2 M4nkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\2NY57UUN3ME2xMlU3PjdizszN NWLFd|JUW0GQR1XS
GR-ST MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUGyS4tCUUN3ME2xMlU3QDJizszN NH7tOYZUSU6JRWK=
RPMI-8866 NYnZZ4czT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTFwNkCxOFQh|ryP MUfTRW5ITVJ?
KG-1 MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTFwNkG5NFEh|ryP MoL4V2FPT0WU
NCI-H82 NYjoTYFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTFwNkO0NFYh|ryP MYfTRW5ITVJ?
LB1047-RCC M4C5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFwNkO0OVkh|ryP NXvLd2JrW0GQR1XS
KM12 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTFwNkS3JO69VQ>? MnPnV2FPT0WU
NB5 MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnwWoJKSzVyPUGuOlU3PzdizszN M3PyNXNCVkeHUh?=
HDLM-2 NF7ZTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml25TWM2OD1zLk[4NlgyKM7:TR?= NY\C[mlsW0GQR1XS
KU812 NIPuOnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFwNkm2NFUh|ryP MYXTRW5ITVJ?
DB NFXSfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXtTWM2OD1zLkewN|U{KM7:TR?= NVXVd4lWW0GQR1XS
HD-MY-Z M1H3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTsNWpKSzVyPUGuO|UzOzRizszN M{W5OHNCVkeHUh?=
KURAMOCHI MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFW1emNKSzVyPUGuO|czODdizszN NYHn[oZJW0GQR1XS
ETK-1 MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlj1TWM2OD1zLke4PFc6KM7:TR?= MVXTRW5ITVJ?
SK-UT-1 MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTFwN{mzPFgh|ryP NXvqfFRVW0GQR1XS
HUTU-80 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXPPGlEUUN3ME2xMlc6PTB6IN88US=> NF3rcIZUSU6JRWK=
ES7 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzVTWM2OD1zLkiwN|AzKM7:TR?= MYjTRW5ITVJ?
SW872 M1zUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHuTWM2OD1zLkixN|k2KM7:TR?= M2fPe3NCVkeHUh?=
TK10 NXnoWI82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPIfHNKSzVyPUGuPFMyODhizszN MUPTRW5ITVJ?
LB831-BLC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTXPI1JUUN3ME2xMlg{PTZ|IN88US=> NV;VbmozW0GQR1XS
TE-9 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmiyTWM2OD1zLki0OFIzKM7:TR?= M{nOXnNCVkeHUh?=
MLMA MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFwOEiyN|Qh|ryP NFP2eoFUSU6JRWK=
D-542MG MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTFwOEmzO|Mh|ryP M4\6[XNCVkeHUh?=
EW-16 MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnCTWM2OD1zLkmyO|Ih|ryP NXnRS4xXW0GQR1XS
LOXIMVI MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTFwOUOyPEDPxE1? MoXFV2FPT0WU
GB-1 MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzvZ3JxUUN3ME2xMlk{QDZ4IN88US=> NWe0R5JYW0GQR1XS
IST-SL2 NH22cJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJwMECyOlIh|ryP MUjTRW5ITVJ?
LAN-6 M{[5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vPR2lEPTB;Mj6wNVk3PiEQvF2= MlLYV2FPT0WU
NCI-H510A MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrpbIdNUUN3ME2yMlA1PTB{IN88US=> NGizbnpUSU6JRWK=
NCI-H1092 MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnCfGtkUUN3ME2yMlA2OTJ2IN88US=> MlyxV2FPT0WU
HT MniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXKc|ZKSzVyPUKuNVA1PTRizszN NVHKTYM5W0GQR1XS
RL95-2 M3jtSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJwMUG0PFIh|ryP MnPtV2FPT0WU
NCI-H1355 M1O4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PPdmlEPTB;Mj6xNVc6OiEQvF2= NEnqVYtUSU6JRWK=
NCI-H720 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnTXpgxUUN3ME2yMlE3QDd|IN88US=> NV\J[IlzW0GQR1XS
NCI-H1522 M3vxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjZcVhsUUN3ME2yMlIyPzJ|IN88US=> MWPTRW5ITVJ?
LB373-MEL-D NV[wWHo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJwMk[5NFIh|ryP Mn7mV2FPT0WU
DG-75 NWi0NndzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f0dmlEPTB;Mj6yO|E1QCEQvF2= MXPTRW5ITVJ?
ML-2 MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXE[HpYUUN3ME2yMlMzQDV3IN88US=> NVHOXppYW0GQR1XS
SF126 NEDwNYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[5VWlEPTB;Mj6zN|A6PCEQvF2= NVW5eHdSW0GQR1XS
MPP-89 MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\BfWIzUUN3ME2yMlM{OTR3IN88US=> M{HFXnNCVkeHUh?=
NCI-H345 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJwM{OyO|ch|ryP NGPRdpRUSU6JRWK=
LS-123 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1u0fWlEPTB;Mj6zOFk{PiEQvF2= NYPqOYlSW0GQR1XS
NB10 NYD0XYF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnUbHVKSzVyPUKuOFExQTJizszN MnvzV2FPT0WU
CGTH-W-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPReXhKSzVyPUKuOFIzPjdizszN NEK5VJZUSU6JRWK=
CP66-MEL MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLhTWM2OD1{LkS3O|ch|ryP NWrGWIo1W0GQR1XS
L-428 NY\Qb|BsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jHN2lEPTB;Mj60PFUzOSEQvF2= MljsV2FPT0WU
DMS-79 MlHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;LXnVKSzVyPUKuOVQyODNizszN MnTVV2FPT0WU
NCI-H1882 NWLGTGx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUmwXoJwUUN3ME2yMlY4PTZ{IN88US=> M{X4NHNCVkeHUh?=
KGN MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHaOG56UUN3ME2yMlc3QDd4IN88US=> MWfTRW5ITVJ?
EW-1 M{nMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fBfmlEPTB;Mj63O|A5OyEQvF2= M1HYUnNCVkeHUh?=
U-266 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4G1OGlEPTB;Mj64OFgzOyEQvF2= MWrTRW5ITVJ?
COLO-320-HSR NHLy[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fBT2lEPTB;Mj64OVY1OSEQvF2= MnjkV2FPT0WU
KMOE-2 M{TkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJwOEe3NVEh|ryP M4HQdXNCVkeHUh?=
BB49-HNC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjBZYVKSzVyPUKuPVI1QCEQvF2= M1TQT3NCVkeHUh?=
GI-1 NH3mTZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;nTWM2OD1{LkmyPVU4KM7:TR?= NHe3XY5USU6JRWK=
NCI-H1304 NXLiN3hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DoSmlEPTB;Mz6wNFUyOSEQvF2= NYHPeFBPW0GQR1XS
NCI-H2227 NVPyTWJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTNwMEKwO|kh|ryP MYXTRW5ITVJ?
U-87-MG MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzjTWM2OD1|LkCzOVE{KM7:TR?= NHHFbm5USU6JRWK=
NCI-H747 M4rQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHYUIMyUUN3ME2zMlA2OjB4IN88US=> M1TrbXNCVkeHUh?=
CTB-1 M4TTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrwXm83UUN3ME2zMlA2Ozd4IN88US=> MVvTRW5ITVJ?
RPMI-8226 NF;kWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XlbGlEPTB;Mz6xOFM4QCEQvF2= M1\Hb3NCVkeHUh?=
NCI-H2141 NVjlbId6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT6TWM2OD1|LkG2OVY3KM7:TR?= MVjTRW5ITVJ?
IST-MES1 NIfuW|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPhTWM2OD1|LkG4Nlc6KM7:TR?= MXrTRW5ITVJ?
TE-5 M2[4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTNwMkGzOFIh|ryP NFvjVYFUSU6JRWK=
UACC-257 NYThT5hIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTNwNEO2OVkh|ryP NYLvS2J7W0GQR1XS
SK-N-FI M1\jUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfETWM2OD1|LkS1NlI4KM7:TR?= MUfTRW5ITVJ?
MFH-ino NGHIUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkGxTWM2OD1|LkS2OVg6KM7:TR?= NXH1NGJ2W0GQR1XS
SF268 M2jGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nHcWlEPTB;Mz60PFE4PCEQvF2= M4TnPXNCVkeHUh?=
TE-12 Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUW5WJFxUUN3ME2zMlUyPjl7IN88US=> MmLpV2FPT0WU
NB6 M4DLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTPTnZ[UUN3ME2zMlU2PTZ|IN88US=> MYPTRW5ITVJ?
DJM-1 M2jXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17ZNWlEPTB;Mz61PVg6QSEQvF2= NX3FVXFNW0GQR1XS
MZ1-PC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD0TWM2OD1|Lk[xOlI1KM7:TR?= M3viSHNCVkeHUh?=
OCI-AML2 NHHoWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXITWM2OD1|Lk[yOlcyKM7:TR?= MYjTRW5ITVJ?
NCI-H1155 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\0TWM2OD1|LkewPVQ4KM7:TR?= MV3TRW5ITVJ?
RKO NHS2TFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PLOGlEPTB;Mz63O|E5QSEQvF2= MnTMV2FPT0WU
ECC4 NGHIT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXntOXpnUUN3ME2zMlk4OTl3IN88US=> NV[0dm92W0GQR1XS
BB65-RCC NHKxWZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDlUolVUUN3ME2zMlk4PTR5IN88US=> MYPTRW5ITVJ?
EB-3 NXflV5RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELOZYRKSzVyPUOuPVk3OzNizszN NWDT[G5zW0GQR1XS
SHP-77 MnfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\ERmVKSzVyPUSuNFA2OjRizszN MXvTRW5ITVJ?
NCI-H2196 MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHJTWM2OD12LkC1OlI2KM7:TR?= M3XsRXNCVkeHUh?=
GI-ME-N NGfSVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3TUldKSzVyPUSuNFY{QTlizszN NVKzV403W0GQR1XS
MN-60 NV;RUZBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTRwMUC4O{DPxE1? M{\T[HNCVkeHUh?=
NCI-H1694 MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPDPHlRUUN3ME20MlE{PDB3IN88US=> MYjTRW5ITVJ?
LU-65 M3TGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTRwMUWzN|Ih|ryP NVu0TYJLW0GQR1XS
NCI-H1436 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3JTWM2OD12LkG4N|M{KM7:TR?= NEL5[XdUSU6JRWK=
KINGS-1 NYryTVZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHDRm9KSzVyPUSuN|E1OzJizszN NEXQW5FUSU6JRWK=
GT3TKB M4fJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PlTmlEPTB;ND6zN|I3QCEQvF2= NGPscmRUSU6JRWK=
Becker M2njVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XYeWlEPTB;ND6zO|MyOiEQvF2= MnPIV2FPT0WU
HCC1187 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3KzdGlEPTB;ND64PVY2PyEQvF2= NVm0PIg1W0GQR1XS
D-502MG MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTVwMEC0NVYh|ryP M3vZUXNCVkeHUh?=
VA-ES-BJ MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTZOWNtUUN3ME21MlE{Pzd6IN88US=> M1XLVXNCVkeHUh?=
NB7 NIDUWXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mme2TWM2OD13LkG0NVEzKM7:TR?= MWjTRW5ITVJ?
SW962 NEe3SJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTVwM{i4NVQh|ryP MYHTRW5ITVJ?
no-11 Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTVwN{[zOFMh|ryP MlX1V2FPT0WU
KNS-81-FD M2XsOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zzb2lEPTB;NT65NFY6PCEQvF2= MlnaV2FPT0WU
COLO-684 NVHCW4w4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTkXlBKSzVyPUWuPVk1QTRizszN MVfTRW5ITVJ?
D-263MG NXTQS4hOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTZwMEi4PVUh|ryP NV\MTYZDW0GQR1XS
EW-24 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXxOZZxUUN3ME22MlI5PTFizszN NVzEbndJW0GQR1XS
TE-10 NFvlSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPrTWM2OD14LkSyOlI{KM7:TR?= NXLJZVBIW0GQR1XS
EKVX MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XoR2lEPTB;Nj60OlMzOSEQvF2= M2roXnNCVkeHUh?=
NCI-H1648 M2i2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzhTWRKSzVyPU[uOlc2PTdizszN NYTNSoljW0GQR1XS
LB771-HNC M{jnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlX3TWM2OD14LkmyN|AyKM7:TR?= NXvZ[mZ2W0GQR1XS
SK-MEL-1 NIPOZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIOxT3RKSzVyPUiuNVMyPjZizszN MUfTRW5ITVJ?
COLO-668 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRThwMke3PFYh|ryP NF7HSmNUSU6JRWK=
EW-12 NIjhbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHoZ|RGUUN3ME24MlQxQDB|IN88US=> M1rhfnNCVkeHUh?=
A253 MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUKwdFRuUUN3ME24Mlg1PjZzIN88US=> NEe1UlVUSU6JRWK=
NCI-H2126 NHLBWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXJdZlxUUN3ME24Mlg6OzF7IN88US=> NX3HOnRYW0GQR1XS
Calu-6 Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRThwOUmwOFIh|ryP NGfTepdUSU6JRWK=
NCI-H23 NUP4TIJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnGdllKSzVyPUmuNVc4PDZizszN NH3wPJJUSU6JRWK=
WSU-NHL MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXr3SYJ4UUN3ME25Mlc4PDd6IN88US=> NXPQcJJQW0GQR1XS
MMAC-SF NYTDUFJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zqUWlEPTB;OT65O|kxPCEQvF2= MoO3V2FPT0WU
SK-LMS-1 M17mdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHO4dY9KSzVyPUGwMlI5OzRizszN NGX1[4VUSU6JRWK=
GCIY M{jLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnS1TWM2OD1zMD61PVI1KM7:TR?= M3zLUHNCVkeHUh?=
TE-15 NH;KNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\CfVZKSzVyPUGxMlYxODRizszN NHPXWFhUSU6JRWK=
EoL-1-cell MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXCcGJDUUN3ME2xNU44Pjh{IN88US=> NWPXUHVmW0GQR1XS
NCI-H2081 M3O0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTFzLke3PFYh|ryP NYDNe4xTW0GQR1XS
EW-3 M{XFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHjTWM2OD1zMj6yOFY{KM7:TR?= NWPJVm9xW0GQR1XS
CAS-1 NXvydnpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWS1b5pXUUN3ME2xNk4{PjNzIN88US=> NHnxXXBUSU6JRWK=
C2BBe1 NGXPPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfqTI9KSzVyPUGyMlYyOzFizszN MlzGV2FPT0WU
D-247MG M37Hfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PGeGlEPTB;MUKuO|k2OiEQvF2= MkLXV2FPT0WU
NCI-SNU-5 NH7XbI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPDTWM2OD1zMj64NFE{KM7:TR?= NHTBb3RUSU6JRWK=
LS-1034 NYrUV|lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF2LkO5O|Uh|ryP M{Due3NCVkeHUh?=
EW-18 MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTF2LkS0PEDPxE1? MkPTV2FPT0WU
Raji M{nNWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF2LkWwOFkh|ryP Ml\HV2FPT0WU
D-283MED M3HHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnxbWFKSzVyPUG0MlYzPzFizszN NWixW|k6W0GQR1XS
MZ2-MEL NU[5Z4NGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHW3eodKSzVyPUG0Mlk3QTZizszN MVvTRW5ITVJ?
NCI-SNU-16 NVzvXWpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{G0UWlEPTB;MUWuOFY{OyEQvF2= NVP0[YhQW0GQR1XS
P30-OHK NYHwWHUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFX6W|lKSzVyPUG3Mlc5OzFizszN Mn;TV2FPT0WU
RXF393 M1LKUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[yRotKSzVyPUG5MlAyQDZizszN M1LIUHNCVkeHUh?=
NCI-H1395 NEfXdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NET3fGdKSzVyPUKwMlY4ODNizszN MXHTRW5ITVJ?
U-698-M M4DZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7kTWM2OD1{MD63NFc2KM7:TR?= MWHTRW5ITVJ?
NCI-SNU-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHz1c|JKSzVyPUKwMlczOjNizszN NV:zRWJ6W0GQR1XS
SW684 NIPrSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTsbGpGUUN3ME2yNU4yPzF4IN88US=> MUDTRW5ITVJ?
NCI-H716 NHjKTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7YVFNKSzVyPUKxMlMyPTRizszN MYfTRW5ITVJ?
JVM-2 MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\vRmlEPTB;MkGuOFE{OyEQvF2= MXLTRW5ITVJ?
NCI-H1581 NVKxT25ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUewbG05UUN3ME2yNk41OTR6IN88US=> NEiwdVJUSU6JRWK=
CA46 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrzUZZKSzVyPUOxMlY6OzZizszN MVPTRW5ITVJ?
SNB75 M2DqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7hdJgzUUN3ME2zN{43PTB|IN88US=> Ml34V2FPT0WU
KNS-42 NF;Tc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTN3Lkm2NlQh|ryP NGDNOVdUSU6JRWK=
TUR NV\3cnhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LBTGlEPTB;M{[uNFUzOSEQvF2= NEDxRWxUSU6JRWK=
REH NELPVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\I[WlEPTB;M{euPFIyOSEQvF2= M{fpRnNCVkeHUh?=
EW-22 NUPB[XFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTR{LkK4PFUh|ryP M{fjWHNCVkeHUh?=
NCI-H446 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvxNndMUUN3ME20Nk44QDV|IN88US=> M{XGOHNCVkeHUh?=
ES3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTR|LkGzN|kh|ryP NYnlNnJOW0GQR1XS
EW-11 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M332RmlEPTB;NESuPFIyQCEQvF2= MUnTRW5ITVJ?
RH-1 NEj2T5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTR5LkW4NVIh|ryP MnzwV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; 

PubMed: 24203492     


HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. 

Cleaved PARP; 

PubMed: 19148581     


Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control.

Caspase 8 ; 

PubMed: 19148581     


Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression.

DR4 / DR5; 

PubMed: 19148581     


Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h.

TopoIIα / TopoIIβ; 

PubMed: 21254166     


Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.

24203492 19148581 21254166
Immunofluorescence
phalloidin / snail; 

PubMed: 29855565     


(C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed.

DR4 / DR5; 

PubMed: 19148581     


Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls.

H3K4Me3 / H3K9Me3; 

PubMed: 22468166     


Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.

29855565 19148581 22468166
Growth inhibition assay
Cell proliferation; 

PubMed: 24203492     


(A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. *, P < 0.05, **; P ≤ 0.01; ***, P ≤ 0.001

Cell viability; 

PubMed: 28969017     


PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.

24203492 28969017
ELISA
GCP-2 / MCP-2 / MIF ; 

PubMed: 24241152     


MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).

24241152
In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

- Collapse

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

- Collapse
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275
Smiles C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03829930 Recruiting Drug: Entinostat|Drug: Enzalutamide Prostate Adenocarcinoma George Washington University May 1 2019 Phase 1
NCT03765229 Recruiting Drug: Entinostat|Drug: Pembrolizumab Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 22 2019 Phase 2
NCT03473639 Recruiting Drug: Entinostat|Drug: Capecitabine Metastatic Breast Cancer|Breast Cancer University of Virginia|Syndax Pharmaceuticals January 29 2019 Phase 1
NCT03361800 Active not recruiting Drug: Entinostat Breast Cancer|Invasive Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals|National Cancer Institute (NCI) November 28 2018 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID